---
title: "BrainAurora joins Beijing Frontier BCI Institute to accelerate clinical translation of brain-computer interface technologies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281455099.md"
description: "BrainAurora Medical Technology Limited has partnered with the Beijing Frontier Brain-Computer Interface Institute to enhance clinical translation of brain-computer interface (BCI) technologies. This collaboration aims to develop initiatives like a neurological disease database and BCI products, addressing the needs of over 100 million patients with neurological disorders in China. The partnership aligns with Beijing's goal to establish a leading BCI research hub. The latest analyst rating for BrainAurora (HK:6681) is a Hold with a price target of HK$4.00."
datetime: "2026-04-01T23:52:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281455099.md)
  - [en](https://longbridge.com/en/news/281455099.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281455099.md)
---

# BrainAurora joins Beijing Frontier BCI Institute to accelerate clinical translation of brain-computer interface technologies

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

BrainAurora Medical Technology Limited ( (HK:6681) ) just unveiled an announcement.

BrainAurora Medical Technology Limited has become a strategic partner of the newly established Beijing Frontier Brain-Computer Interface Institute, founded under the initiative of Xuanwu Hospital, Capital Medical University, to drive breakthroughs and clinical translation in brain-computer interface technologies. The partnership aligns BrainAurora’s cognitive impairment digital therapeutics expertise with Beijing’s push to build a leading, world-class BCI research and development hub.

Under a strategic cooperation agreement signed on March 27, 2026, BrainAurora and the Institute will jointly develop key initiatives such as a multimodal neurological disease database, a neuroelectrophysiological large-scale model, and closed-loop neuromodulation BCI products. The collaboration is expected to accelerate full-chain clinical translation of BCI technologies in China, address the needs of more than 100 million patients with neurological disorders, and strengthen an innovation ecosystem that tightly integrates engineering, medical sciences, and industry-academia cooperation.

The most recent analyst rating on (HK:6681) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on BrainAurora Medical Technology Limited stock, see the HK:6681 Stock Forecast page.

**More about BrainAurora Medical Technology Limited**

BrainAurora Medical Technology Limited is a China-focused medical technology company specializing in digital therapeutics for cognitive impairment, combining brain science with artificial intelligence. Through its subsidiaries, including Zhejiang BrainAurora Medical Technology Co., Ltd., the group targets the rapidly developing brain-computer interface sector and broader high-end medical equipment market, with an emphasis on clinical applications in medical rehabilitation.

**Average Trading Volume:** 25,740,614

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$5.61B

### Related Stocks

- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [06681.HK](https://longbridge.com/en/quote/06681.HK.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium](https://longbridge.com/en/news/286258287.md)
- [Should Interface’s Upgraded 2026 Outlook and Open Air Expansion Require Action From TILE Investors?](https://longbridge.com/en/news/286843203.md)
- [Kepler Capital  Keeps Their Buy Rating on Rai Way S.p.A. (0R40)](https://longbridge.com/en/news/286183642.md)
- [Antalpha Announces Strategic Expansion Into AI Infrastructure | ANTA Stock News](https://longbridge.com/en/news/286820518.md)